Centessa Pharmaceuticals plc
CNTA
$11.57
$0.302.66%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.43% | -10.45% | -11.74% | -10.11% | -2.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.87% | -5.18% | -12.98% | -20.48% | -15.29% |
| Operating Income | -17.38% | 9.03% | 16.66% | 23.77% | 18.55% |
| Income Before Tax | -32.23% | 14.09% | 19.81% | 23.01% | 18.81% |
| Income Tax Expenses | 111.35% | 110.94% | 97.95% | -16,734.67% | -3,254.22% |
| Earnings from Continuing Operations | -56.04% | -2.44% | 8.86% | 34.84% | 30.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.04% | -2.44% | 8.86% | 34.84% | 30.12% |
| EBIT | -17.38% | 9.03% | 16.66% | 23.77% | 18.55% |
| EBITDA | -17.39% | 9.11% | 16.76% | 23.89% | 18.64% |
| EPS Basic | -26.63% | 7.78% | 14.59% | 36.92% | 32.16% |
| Normalized Basic EPS | 4.56% | 21.75% | 23.32% | 25.44% | 21.49% |
| EPS Diluted | -26.63% | 7.78% | 14.59% | 36.92% | 32.16% |
| Normalized Diluted EPS | 4.56% | 21.75% | 23.32% | 25.44% | 21.49% |
| Average Basic Shares Outstanding | 18.98% | 11.07% | 6.57% | 3.08% | 2.98% |
| Average Diluted Shares Outstanding | 18.98% | 11.07% | 6.57% | 3.08% | 2.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
